問卷

TPIDB > Search Result

Search Result

篩選

List

52Cases

2025-05-01 - 2030-04-30

Phase III

Active
A global, multicenter, randomized, open-label phase 3 trial comparing sacituzumab govitecan with standard of care (SOC) in previously treated extensive-stage small cell lung cancer (ES-SCLC) participants.
  • Condition/Disease

    ORR is defined as the percentage of participants who achieve a complete response (CR) or a partial response (PR) as assessed by BICR according to RECIST v1.1. OS is defined as the length of time elapsed from random assignment until the date of death from any cause.

  • Test Drug

    TRODELVY for Injection

Participate Sites
9Sites

Recruiting9Sites

2020-12-01 - 2027-12-31

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-11-01 - 2030-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2025-06-01 - 2028-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-05-01 - 2030-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-08-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2023-05-01 - 2026-06-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-11-02 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-09-15 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting6Sites

Terminated6Sites

2019-06-10 - 2026-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites